ReviewEcancermedicalscience2014
Adaptive immunity in cancer immunology and therapeutics.
Review in Ecancermedicalscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Significantly mutated genes and regulatory pathways in SCLC-a meta-analysis.Cancer genetics · 2017Pooled it
- Understanding the Lymph Node Microenvironment in Metastatic and Non-Metastatic Head and Neck Squamous Cell Carcinoma: A Systematic Review.Journal of personalized medicine · 2026Review
- Review
- Adoptive cell therapy for high grade gliomas using simultaneous temozolomide and intracranial mgmt-modified γδ t cells following standard post-resection chemotherapy and radiotherapy: current strategy and future directions.Frontiers in immunology · 2024Article
- HK3 stimulates immune cell infiltration to promote glioma deterioration.Cancer cell international · 2023Article
- Fluorogenic Granzyme A Substrates Enable Real-Time Imaging of Adaptive Immune Cell Activity.Angewandte Chemie (International ed. in English) · 2023Article
- Fluorogenic Granzyme A Substrates Enable Real-Time Imaging of Adaptive Immune Cell Activity.Angewandte Chemie (Weinheim an der Bergstrasse, Germany) · 2023Article
- Overcoming physiological barriers by nanoparticles for intravenous drug delivery to the lymph nodes.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- In vitro assessment of antitumor immune responses using tumor antigen proteins produced by transgenic silkworms.Journal of materials science. Materials in medicine · 2021Article
- Life and Death Decision-Making by p53 and Implications for Cancer Immunotherapy.Trends in cancer · 2021Review
- Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review.International journal of molecular sciences · 2020Review
- Review
- Inhibition of host NOX1 blocks tumor growth and enhances checkpoint inhibitor-based immunotherapy.Life science alliance · 2019Article
- High Expression of HLA-G in Ovarian Carcinomatosis: The Role of Interleukin-1β.Neoplasia (New York, N.Y.) · 2019Article
- Lambda bacteriophage nanoparticles displaying GP2, a HER2/neu derived peptide, induce prophylactic and therapeutic activities against TUBO tumor model in mice.Scientific reports · 2019Article
- Pneumonitis in Combined Anti-programmed Death-1 Immunotherapy and Radiation Therapy for Renal Cell Carcinoma.Cureus · 2018Article
- Bioactive Nanoparticles for Cancer Immunotherapy.International journal of molecular sciences · 2018Review
- Key Immunological Functions Involved in the Progression of Epithelial Ovarian Serous Carcinoma Discovered by the Gene Ontology-Based Immunofunctionome Analysis.International journal of molecular sciences · 2018Article
- Prognostic role of the neutrophil-to-lymphocyte ratio in patients with primary central nervous system lymphoma.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The vast genetic alterations characteristic of tumours produce a number of tumour antigens that enable the immune system to differentiate tumour cells from normal cells. Counter to this, tumour cells have developed mechanisms by which to evade host immunity in their constant quest for growth and survival. Tumour-associated antigens (TAAs) are one of the fundamental triggers of the immune response. They are important because they activate, via major histocompatibility complex (MHC), the T cell response, an important line of defense against tumourigenesis. However, the persistence of tumours despite host immunity implies that tumour cells develop immune avoidance. An example of this is the up-regulation of inhibitory immune checkpoint proteins, by tumours, which induces a form of self-tolerance. The majority of monoclonal antibodies in clinical practice have been developed to target tumour-specific antigens. More recently there has been research in the down-regulation of immune checkpoint proteins as a way of increasing anti-tumour immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.